Last updated: 2026-09-09 09:36:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
NeoGenomics, Inc. (NEO) operates in the SERVICES-TESTING LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $17.59, with a market capitalization of $2.23B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.07 to $19.76. This page covers its latest market performance, valuation, price trends and company information.
$2.23B | |
$17.74 | |
$61.57 | |
$2.05 | |
$17.56 | |
4.82K | |
2.85M | |
-- | |
$19.76 | |
$7.07 | |
-- | |
-- |
NeoGenomics, Inc. (NEO) is trading at $17.59 in pre-market trading as of 2026-09-09 09:15:00, up 0.19% ($0.03) from the previous close of $17.56
Pre-market trading shows how investors are pricing NEO before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, NeoGenomics, Inc. (NEO) moved from $18.05 to $17.59, representing a decline of 2.53% ($0.46).
The stock traded between $16.87 and $18.75 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.54 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82.9%
NEO is currently trading at $17.59, placing it 82.9% of the way from its 52-week low of $7.07 to its 52-week high of $19.76. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
| Industry | SERVICES-TESTING LABORATORIES |
| Employees | 2500 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NeoGenomics, Inc. (NEO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.